Contera Pharma has developed new strategies to identify drug development projects characterized by high probability of success,
fast access to clinical development and long exclusivity.
Movement disorders are a group of diseases that affect the ability to produce and control body movement,
and are often associated with neurological disorders or conditions associated with neurological dysfunction.
One example of a movement disorder is dyskinesia which characterized by various involuntary movements,
which can affect discrete body parts or can become generalized and severely disabling.
Contera Pharma develops new innovative treatments of movement disorders.
The lead project JM-010 is approved to start Phase IIa studies for treatment of L-DOPA induced dyskinesia. Contera Pharma in addition,
explores preclinical projects to treat or prevent other movement disorders like Parkinson's disease and tardive dyskinesia.